600380
XSHG
Market cap2.79bUSD
Nov 20, Last price
10.19CNY
1D
-1.45%
1Q
3.14%
Jan 2017
13.35%
IPO
125.94%
Name
Joincare Pharmaceutical Group Industry Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Joincare Pharmaceutical Group Industry Co., Ltd. is a Chinese enterprise primarily focused on the comprehensive process of researching, developing, producing, and commercializing pharmaceutical and healthcare products within China. The company boasts a broad pharmaceutical portfolio that includes both Western chemical drug preparations, addressing conditions such as respiratory, gastrointestinal, anti-infection, gonadotropic, and psychiatric disorders, as well as traditional Chinese medicines (TCM), with offerings for anti-tumor and cold relief. Beyond finished drugs, Joincare supplies chemical active pharmaceutical ingredients (APIs) and intermediates. Its operations also extend into the diagnostics sector, where it provides specialized reagents and equipment, such as an autoimmunity multiple detection platform and an IgM diagnostic kit. Furthermore, the company markets a range of health and wellness products, exemplified by American ginseng tea and Jingxin menocare essence. Joincare diversifies its business by engaging in the wholesale and retail of personal care items, including skincare products, cosmetics, and various other essential goods. Its products are available in diverse formats, such as hormone tablets, oral liquid formulations, and standard tablets. Established in 1992, Joincare Pharmaceutical Group maintains its principal offices in Shenzhen, China.
Key people
Guangxia Liu
Vice Chairman of the Board · since 2021
Finance Director, Vice President, Director · since 2020
Yanmei Du
Vice President · since 2024
Tingke Tang
Vice President · since 2024
Qinglei Zhang
Vice President · since 2026
Leiming Zhang
Vice President · since 2023
Yifan Zhu
Secretary of the Board · since 2024
President, Director · since 2024
Zhiwei Xing
Vice President, Director · since 2024
Chairman of the Board · since 2005
Jing Huo
Independent Director · since 2021
Juan Peng
Independent Director · since 2021
Yezhi Qin
Independent Director · since 2020
Independent Director · since 2023
Headquarters & legal address
深圳市南山区高新区北区朗山路17号健康元药业集团大厦
深圳市, GD 518000
CN
深圳市, GD 518000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||